Explore the words cloud of the HYPERQTOTAL project. It provides you a very rough idea of what is the project "HYPERQTOTAL" about.
The following table provides information about the project.
BSP BIOLOGICAL SIGNAL PROCESSING LTD
|EC max contribution
|50˙000 € (70%)
1. H2020-EU.3.1.3. (Treating and managing disease)
|from 2016-02-01 to 2016-04-30
Take a look of project's partnership.
|BSP BIOLOGICAL SIGNAL PROCESSING LTD
|IL (TEL AVIV)
Occlusion of the coronary arteries that supply oxygenated blood to the heart muscle is referred to as ischemic heart disease (IHD). IHD is the most common, serious, chronic, life-threatening illness in the developed world. Currently, the most widely used tool for diagnosing IHD is the electrocardiogram (ECG), which records the electrical activity of the cardiac muscle as it generates the stages of the cardiac cycle. Specific changes in the ECG recorded during physical stress protocols are used for the non-invasive detection of IHD. Patients with positive stress test results are usually referred for further investigation. However, the sensitivity of the standard ECG, even during stress tests, is relatively poor, and is generally considered to be between 50% and 70%, and in some studies has been reported to be even lower. That, in other words, means that 30-50% of all IHD patients are not diagnosed correctly by standard stress ECGs. Traditional ECG analysis is performed in the 0.05 – 100Hz frequency range. However, a significant body of evidence accumulated during recent years indicates that higher frequency spectral components of the ECG signal contain valuable information for the detection of IHD. Studies published by Prof. Shimon Abboud, BSP’s chief scientist, and Dr. Amir Beker, BSP’s founder and CEO, have shown that the presence of ischemic pathologies in the heart is highly correlated with specific changes in the high-frequency spectral components of the ECG. BSP has pioneered the clinical implementation of high-frequency ECG and has developed it into a valuable diagnostic application. The company’s proprietary HyperQ™ technology extracts and analyses the high-frequency components of the ECG. BSP has pursued the development of its HyperQ™ technology in two parallel, highly correlated, pathways: (a) acquisition and reliable production of the HyperQ™ signal, and (b) analysis of the HyperQ™ signal for extracting clinical and diagnostic information.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPERQTOTAL" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HYPERQTOTAL" are provided by the European Opendata Portal: CORDIS opendata.
ENDOSCAPE, a clinically applicable non-viral gene delivery technologyRead More
Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trialRead More
European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer developmentRead More